Articles Posted in Mesothelioma Medical

When patients are diagnosed with a debilitating disease such as cancer, their focus often immediately shifts towards whether or not they will require surgery to treat the disease and what, if any, are the least invasive and most effective treatment options. Some forms of cancer can be treated without surgery, using radiation or chemotherapy, if caught in the early stages, while others leave patients with limited treatment options that may leave surgery as the only course of action.

A recent European study compared surgical treatments in patients diagnosed with malignant pleural mesothelioma, a rare and deadly form of cancer affecting the thin lining of tissue surrounding the lungs. The researchers compared data of two types of treatments performed from 1999 through 2018, pleurectomy/decortication (P/D) and extrapleural pneumonectomy (EPP) to see if patients fared better with one treatment over the other in terms of survival.

Mesothelioma has a particularly long latency period, which is the time between exposure to a carcinogen and when a diagnosis is actually made. The disease’s latency period can be anywhere from 20 years to 50 years, which can leave patients with especially limited treatment options and make surgery the only treatment available to prolong the individual’s lifespan.

A pair of recent studies suggest that a certain treatment may be able to help treat mesothelioma, a rare and deadly form of cancer that often affects the thin lining of tissue surrounding the lungs, but may also affect other parts of the body. The treatment, called talc pleurodesis, is a surgical procedure to help prevent pleural effusions, which is when fluid builds around the lungs, making it hard for the patient to breathe and allow the disease to spread.

In a recent study published by the Journal of Thoracic Disease, researchers found that the procedure improves survival rates of patients better than some other lung fluid treatments. The results further suggest that the treatment, which is less invasive than others, may be a better quality of life option than more aggressive surgery to remove tumors surrounding the lungs.

The study, conducted by Dr. Emanuela Taioli of the Institute of Translational Epidemiology at Ichan, examined almost 50 other studies focused on the survival rates of patients who underwent talc pleurodesis compared to those who underwent surgery. Research showed that on average, the survival rate of patients treated with talc pleurodesis was 14 months, compared to 17 months for those who underwent invasive surgery, like pleurectomy and decortication, and 24 months for even more aggressive surgeries like extrapleural pneumonectomy.

A Memphis, Tennessee hospital recently began using a first of its kind electric therapy treatment approved by the Food and Drug Administration (FDA) to treat the progression of mesothelioma, a rare and deadly form of lung cancer caused by exposure to asbestos fibers. “Because it is such a rare cancer, there has been little research opportunities to advance science and treatment of mesothelioma,” said Dr. Moon Fenton, West Cancer Center hematologist while speaking to local media.

For decades, doctors treated mesothelioma through a combination of surgery, radiation treatment, and chemotherapy. Now, doctors will have access to a fourth treatment option via the NovoTTF-100. The devices functions by attaching three to the front and back of the patient’s chest and sending electric fields into the body to target and disrupt mesothelioma cancer cells from growing and spreading, all while allowing healthy cells to remain intact.

“We are looking at 97% disease control at year one. So, patients who are using this technology in addition to the chemotherapy actually have stable disease or great response to treatment,” said Dr. Fenton in a local NBC interview. “This treatment is not invasive, and has minimal side effects.” Patient’s at Dr. Fenton’s hospital, West Cancer Center, will wear the device for 18 hours per day to treat mesothelioma.